ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis’ canakinumab fails to meet primary endpoint in lung cancer trial
March 10, 2021Novartis has reported that the Phase III CANOPY-2 study of canakinumab (ACZ885) in combination with the chemotherapy agent docetaxel failed to meet the primary endpoint of overall survival (OS) in patients with advanced or metastatic non-small cell ...
Pharma Sources Insight January 2025
